Showing 7191-7200 of 9283 results for "".
- FDA Takes First Step Toward Expanding Sunscreen Optionshttps://practicaldermatology.com/news/fda-takes-first-step-toward-expanding-sunscreen-options/2484881/The American Academy of Dermatology Association (AADA) released a statement from organization president Susan C. Taylor, MD, FAAD commending the Food and Drug Administration (FDA) for taking its first significant step in more than 20 years toward expanding safe and
- Survey Shows Common Skin Cancer Terms Often Misunderstoodhttps://practicaldermatology.com/news/common-skin-cancer-terms-often-misunderstood-survey-finds/2484880/A research letter looking at how well patients understand commonly used terminology related to skin published in JAMA Dermatology revealed significant gaps that could hinder informed decision-making, according to the study r
- Systematic Review Shows BTX Effective for Ischemic Digital Complicationshttps://practicaldermatology.com/news/systematic-review-btx-effective-for-ischemic-digital-complications/2484841/Botulinum toxin (BTX) injections may offer a promising rescue therapy for patients with refractory digital ischemia, ulcers, or gangrene associated with systemic sclerosis and other vasculopathies, according to findings from a systematic review in
- Real-World Study Confirms Ixekizumab Outperforms Ustekinumab in Psoriasishttps://practicaldermatology.com/news/real-world-study-confirms-ixekizumab-outperforms-ustekinumab-in-psoriasis/2484790/A recent real-world studyreplicated the results of the IXORA-S trial, which demonstrated the efficacy of ixekizumab over ustekinumab for treating moderate-to-severe plaque psoriasis. Researchers for the observational analysis, c
- New Series Spotlights Real Stories of MCC Patientshttps://practicaldermatology.com/news/new-series-spotlights-real-stories-of-mcc-patients/2484808/The Skin Cancer Champions Community announced that it will launch its Living With: Merkel Cell Carcinoma (MCC) web series on Wednesday, January 14, 2026, from 12:00 to 1:00pm EST via Zoom. According to a release from the group, the premiere episode,
- Oral Roflumilast Suppresses Psoriatic Inflammation at the Gene and Cellular Level: Studyhttps://practicaldermatology.com/news/oral-roflumilast-suppresses-psoriatic-inflammation-at-the-gene-and-cellular-level/2484789/In a mechanistic substudy of the PSORRO trial, oral roflumilast demonstrated targeted immunomodulatory effects in patients with moderate-to-severe plaque psoriasis. Researchers for the vivo analysis sourght to characterize the dru
- Study: Tirzepatide Shows Early Efficacy in Hidradenitis Suppurativahttps://practicaldermatology.com/news/study-tirzepatide-shows-early-efficacy-in-hidradenitis-suppurativa/2484716/New research shows dual GLP-1/GIP inhibitor tirzepatide, a dual GLP-1/GIP receptor agonist currently approved for type 2 diabetes and obesity, may offer a novel therapeutic option for patients with moderate-to-severe hidradenitis suppurativa (HS), according to a sm
- Lupus-like Skin Disease in MDS/CMML Linked to Clonal Inflammation: Studyhttps://practicaldermatology.com/news/lupuslike-skin-disease-in-mdscmml-linked-to-clonal-inflammation/2484592/Lupus-like manifestations in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) appear to represent a distinct clinical entity driven by clonal hematopoiesis rather than classic autoimmunity, according to a new case-control study
- Platform Prints First Collagen-Based Bioink for Personalized Tissue Creationhttps://practicaldermatology.com/news/platform-prints-first-collagen-based-bioink-for-personalized-tissue-creation/2484559/Conexeu Sciences Inc. has announced the first 3D-printed tissue scaffolds created entirely from its proprietary extracellular matrix (ECM), according to a release from the manufacturer. Conexeu said their CXU™ platform, a bovin
- Trial for First Oral Minoxidil for Female Hair Loss Initiates Phase 3https://practicaldermatology.com/news/trial-for-first-oral-minoxidil-for-female-hair-loss-launches-phase-3/2484534/Veradermics, Inc. announced the initiation of patient enrollment in a phase 2/3 registration-directed clinical trial of VDPHL01, a novel extended-release oral minoxidil formulation, according to a press release. If approved, V